Latest research on Pioglitazone

Pioglitazone is used for the treatment of diabetes mellitus type 2. Pioglitazone selectively stimulates nuclear receptor peroxisone proliferator-activated receptor gamma (PPAR-gamma). It modulates the transcription of the insulin-sensitive genes involved in the control of glucose and lipid metabolism in the lipidic, muscular tissues and in the liver.

Latest findings

All the surrogate CV markers positively influenced by Pioglitazone were put to test [5]. [source, 2016]
The primary end-points in this study failed to achieve statistical significance in spite of a significant glycemic difference between the two arms (−0.8% Pioglitazone versus −0.3% placebo; P < 0.0001) [4]. [source, 2016]
There were significantly higher event rates related to heart failure in the Pioglitazone arm (Table 2). [source, 2016]
Thiazolidinediones(TZDs) such as troglitazone, Rosiglitazone and Pioglitazone are peroxisome proliferator activated receptor-γ(PPARγ) agonists that improve glucose control in patients with type 2 diabetes by enhancing insulin sensitivity in target tissues. [source, 2016]
Thioglitazones such as RGZ and Pioglitazone are potent PPARγ full agonists (PPARγ-fa) that have been largely used so far in the clinical practice. [source, 2016]
Fenofibrate, a PPARα agonist, and Pioglitazone, a PPARγ agonist, are widely used in the clinical setting for the management of dyslipidemia and insulin resistance. [source, 2016]
It is not known whether PPAR activation (Fenofibrate and Pioglitazone treatment) will increase hepatic lipid content by inducing LADPs expression. [source, 2016]
Moreover, we investigated the effects of PPAR activation on the regulation of these LADPs in HFD-induced obese mice treated with Fenofibrate or Pioglitazone for 20 weeks. [source, 2016]
After 1 week of acclimation, the animals were randomly assigned to receive one of the following treatments for 20 weeks: chow diet, HFD (20% of energy as carbohydrates, 20% as protein, and 60% as fat, as a percentage of total kcal, manufactured by SLAC), HFD + Fenofibrate (30 mg/kg body weight, Sigma-Aldrich, St. Louis, MO, USA), and HFD + Pioglitazone (10 mg/kg body weight, Sigma-Aldrich). [source, 2016]
Fasting glucose levels were reduced early in the experimental period in mice treated with either Fenofibrate or Pioglitazone. [source, 2016]